| Catalog No. | AY583024 |
|---|
| Applications | ELISA |
|---|
| Host species | Rabbit |
|---|
| Isotype | IgG |
|---|
| Clonality | Polyclonal |
|---|
| Immunogen | Tocilizumab |
|---|
| Target | Rabbit polyclonal to Actemra. |
|---|
| Specificity | The product is specific for Tocilizumab. This antibody serves as an excellent positive control for Tocilizumab immunogenicity (ADA) assays. |
|---|
| Purification | Purified by antigen affinity column. |
|---|
| Accession | 375823-41-9 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300. |
|---|
| Product Usage Information |
| Application |
Dilution |
| ELISA |
1:5000-1:20000 |
| IHC |
1:50-1:500 |
| WB |
1:500-1:2000 |
|
|---|
| Stability and Storage | The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles. |
|---|
| Background | Tocilizumab (Actemra) is a humanized monoclonal antibody that is developed by Hoffmann–La Roche and Chugai for the treatment of patients with rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. Tocilizumab binds to the interleukin-6 receptor (IL-6R) and blocks its interaction with interleukin 6 (IL-6), hindering IL-6 from exerting its pro-inflammatory effects.
• Evaluation of a biosensor immunoassay for simultaneous characterization of isotype and binding region of human anti-tocilizumab antibodies with control by surrogate standards., PMID:19379704
|
|---|
| Note | For research use only. |
|---|
